Evidence map›Paper›PMID 42421140›Full record

ArticleTrials2026

Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial.

Connor Prosty, Alex Carignan, Adrienne K Chan, Yan Chen, Peter Daley, Nick Daneman, Christopher Kandel, Yves Longtin, Santiago Perez-Patrigeon, Terry Wuerz and 15 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06979609 (Secondary Prophylaxis of Recurrent Clostridioides Difficile Infections During Systemic Antibiotics With Vancomycin), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06979609 phase2 / phase3recruitingnot on this map

Secondary Prophylaxis of Recurrent Clostridioides Difficile Infections During Systemic Antibiotics With Vancomycin: A Randomized Controlled Trial

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2025 to 2029Enrolled300ConditionsClostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated DiseaseArmsOral Vancomycin Prophylaxis, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Connor ProstyFaculty of Medicine, McGill University, Montréal, Québec, Canada. connor.prosty@mail.mcgill.ca.ORCID https://orcid.org/0000-0001-6790-220X
Alex CarignanDepartment of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Adrienne K ChanDivision of Infectious Diseases, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Yan ChenDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Peter DaleyMedicine and Lab Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.
Nick DanemanDivision of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Christopher KandelMichael Garron Hospital, Toronto, ON, Canada.
Yves LongtinJewish General Hospital and Lady Davis Research Institute, Montréal, Québec, Canada.
Santiago Perez-PatrigeonDivision of Infectious Diseases, Department of Medicine, Queen's University, Kingston, ON, Canada.
Terry WuerzDepartment of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
James CheaveauDepartment of Hospitalist Medicine, East Kootenay Regional Hospital, Cranbrook, BC, Canada.
Susy S HotaDivision of Infectious Diseases, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Olusola OgundipeDepartment of Internal Medicine, Cape Breton Regional Hospital, Sydney, NS, Canada.
Theodore S SteinerDepartment of Medicine and BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.
Jennifer L Y TsangDepartment of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
Patrick ArchambaultSt. George Hospital, Lévis, Québec, Canada.
Marco BergevinCité de La Santé de Laval, Laval, Québec, Canada.
James M BrophyDepartment of Medicine and Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada.
Gabriel GirouardDepartment of Infectious Diseases, Georges-L.-Dumont University Hospital, Moncton, NB, Canada.
Ling KongJewish General Hospital and Lady Davis Research Institute, Montréal, Québec, Canada.
Leighanne ParkesJewish General Hospital and Lady Davis Research Institute, Montréal, Québec, Canada.
Sharon ReinblattPatient Representative, Montréal, Québec, Canada.
Derek MacFaddenThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Todd C Lee *Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Québec, Canada.
Emily G McDonald *Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Québec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClostridioides difficile infection (CDI) is a prevalent, morbid, and expensive disease that recurs in approximately 25% of patients despite treatment. Re-exposure to systemic antibiotics is one of the strongest risk factors for recurrence. Observational evidence and two small randomized controlled trials suggest that secondary vancomycin prophylaxis during antibiotic re-exposure may prevent recurrences, but the current evidence is not definitive.

methodsSPORES-V is a Bayesian multicenter phase III double-blind randomized controlled trial. Patients with CDI in the preceding 120 days who are re-exposed to systemic antibiotics will be randomized to receive prophylactic oral vancomycin (125 mg orally twice daily while on antibiotics and then once daily for 7 days afterwards) or an equal schedule of placebo. The primary outcome is CDI recurrence at day 56, analyzed by intention to treat using an adjusted odds ratio. Secondary outcomes include adverse events, discontinuation due to toxicity, longer-term recurrences (120 days), healthcare usage (56 and 120 days), and all-cause mortality (56 and 120 days). SPORES-V has begun recruitment at the McGill University Health Centre site. DISCUSSION: The SPORES-V trial will provide high-quality evidence on the efficacy and safety of secondary vancomycin prophylaxis in the prevention of recurrent CDI.

trial registrationClinicalTrials.gov NCT06979609. Registered on May 13, 2025, https://clinicaltrials.gov/study/NCT06979609 .

Indexed as

Anti-Bacterial AgentsAntibiotic ProphylaxisClostridioides difficileClostridium InfectionsSecondary PreventionVancomycinAdministration, OralBayes TheoremClinical Trials, Phase III as TopicDouble-Blind MethodDrug Administration ScheduleHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicRecurrenceRisk FactorsAnti-Bacterial AgentsVancomycinClinical trialClostridioides difficileProphylaxisProtocolVancomycin

Identifiers

PMID42421140
PMCPMC13632144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.